Skip to content
Biodatica
Start free

Ascentage Pharma Group Inc.

Beijing, Beijing Municipality

OncologyPhase III
Compare Sign in to watch

What changed

Phase I trial registered: A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

2mo agoTrial registeredMay 1, 2026Source filing (opens the source filing in a new tab)

Momentum

91no change

Momentum 91 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

676 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Patent

    Patent granted

    Jan 14, 2025

    assignee: ASCENTAGE PHARMA GROUP CORP LIMITED · PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE

    USPTO · US 12194024 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Jun 11, 2024

    Acute Myeloid Leukemia · RECRUITING · sponsor: Ascentage Pharma Group Inc. · A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

    ClinicalTrials.gov · NCT06389292 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Dec 28, 2021

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · RECRUITING · sponsor: Ascentage Pharma Group Inc. · Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

    ClinicalTrials.gov · NCT05147467 (opens the source filing in a new tab)

  4. Patent

    Patent assigned

    Mar 18, 2021

    assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD. · PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE

    USPTO · US 12194024 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Sep 28, 2020

    Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy · RECRUITING · sponsor: Ascentage Pharma Group Inc. · Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

    ClinicalTrials.gov · NCT04501120 (opens the source filing in a new tab)

  6. Trial

    PHASE1/PHASE2 registered

    Aug 31, 2020

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · RECRUITING · sponsor: Ascentage Pharma Group Inc. · Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

    ClinicalTrials.gov · NCT04494503 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Mar 2, 2020

    CLL/SLL · RECRUITING · sponsor: Ascentage Pharma Group Inc. · Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

    ClinicalTrials.gov · NCT04215809 (opens the source filing in a new tab)

  8. Trial

    PHASE1 registered

    Jun 3, 2019

    Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Ascentage Pharma Group Inc. · A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

    ClinicalTrials.gov · NCT03913949 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources